OBJECTIVES
Health care reforms in the last decade have resulted in improved access to health care services and pharmaceu4cals in Turkey. As a result of this, several measures were taken to control the increasing healthcare expenditures. In recent years, the government has focused on the burden of imported drugs on the Turkish economy and has declared increasing R&D ac4vi4es and suppor4ng local produc4on as the main objec4ves of the 10 th Development Plan. In this respect, the government has targeted to meet 60% of the na4onal pharmaceu4cal need in terms of value through local produc4on. The process will be completed in five phases and pharmaceu4cal companies will be invited to invest for local produc4on of their products. This study aimed at outlining the local produc4on policies in Turkey.
METHODS
Local produc4on of pharmaceu4cals is high on the agendas of Turkish policy-makers. A process comprising of five phases is adopted with expected public savings of 22.3 billion TRY (5.1 billion€). The first phase is completed and 48 medicines will be delisted from the reimbursement list on February 8, 2018. 73% of these products are s4ll reimbursed by the SSI, 19% are passivized in the system and 8% are de-listed with the request of the producer. The majority of these products are in the blood and blood forming organs and nervous system ATC categories.
RESULTS
A literature analysis was made to explore the local produc4on policies in Turkey. A thorough analysis of the de-lis4ng document published by the Turkish Medicines and Medical Devices Agency's (TITCK) web site in April 2017 was made. The list covers 48 products that will be delisted from the reimbursement list as of February 8, 2018. This list was analyzed by using Rx Media © and Social Security Ins4tu4on's (SSI) lists showing the prices and discounts of the products. Other relevant data for the study were obtained from the Turkish Medicines and Medical Devices Agency's presenta4ons.
CONCLUSION
The emphasis on controlling pharmaceu4cal expenditures has reached another stage in Turkey with more emphasis and policies towards local produc4on of products. It is expected that apart from savings on the public budget, there will be an impact on R&D ac4vi4es, on technology transfer and on decreasing current deficit. The Ministry of Health and SSI are working on addi4onal incen4ves for licensing, pricing and reimbursement policies of these locally produced drugs as well. is predicted. Policies will differ among drugs with and without equivalent groups. There will be three stages for drugs with equivalent groups. Local produc4on policies are first applied to drugs with 50% or more local products in the market. Followed by drugs with more than 10% and less than 10% local products. The fourth stage will be applied to imported drugs and fibh stage will be applied to drugs without an equivalent group.
TITCK
As can be seen from Figure 4 , the bulk of the saving from the localiza4on process is planned for Phase IV (63%). The first phase to start in 2018 has the lowest share.
